MENLO PARK, CA--(Marketwire - April 23, 2009) - SRI International, an independent, nonprofit
research and development organization, announced today that Caroline
Tolman-Salinas has been appointed director of Quality Clinical Labs (QCL),
SRI's commercial clinical sample testing laboratory. QCL specializes in
clinical hematology and chemistry evaluations for pharmaceutical and
medical device research applications, and is the oldest established
laboratory of its type in California performing clinical pathology analyses
in full compliance with Good Laboratory Practice (GLP) regulations.
"Ms. Tolman-Salinas is a very experienced clinical laboratory scientist and
manager who is the right leader for the important clinical pathology work
performed by QCL," said Jon Mirsalis, Ph.D., managing director of SRI
International's Biosciences Division. "Over the past year she has made
significant contributions to the lab resulting in major improvements in our
operations."
Tolman-Salinas first joined SRI in February 2008 and has served as the
acting director of QCL since May 2008. She has strengthened compliance with
GLP guidelines and improved efficiency of operations. In her new role, she
will be responsible for overall operations of the lab, including
supervision of staff, technical oversight, and liaison with clients.
Prior to joining SRI, Tolman-Salinas was a clinical laboratory scientist at
Aviir, Inc., where she served in a dual role to establish a clinical
laboratory operation in accordance with industry regulations and assisted
with R&D activities for new cardiac and diabetic clinical assay products.
Her other responsibilities included establishing a clinical laboratory and
a donor phlebotomy program for clinical trials.
Tolman-Salinas has had increasing levels of responsibility in a variety of
clinical laboratories, including XDx, where she contributed to quality
assurance improvements. Her experience also includes Stanford Hospital and
Clinics, where she was a senior virology technologist, and Kaiser
Permanente, where she served as a molecular genetics technologist.
Tolman-Salinas has a B.S. in clinical laboratory science. She holds a
clinical laboratory scientist license from the State of California and is
licensed by the American Society of Clinical Pathologists.
About SRI's Biosciences Division
SRI International's Biosciences Division teams with pharmaceutical and
biotechnology companies, academia, foundations, and government agencies to
solve important problems in global health. SRI Biosciences conducts basic
research, drug discovery, and drug development, including contract
research. SRI has all of the resources necessary to take R&D programs from
"idea to IND"™ -- from initial discovery to investigational new drug
applications to start human clinical trials -- and specializes in cancer,
immunology and inflammation, infectious disease, and neuroscience research.
To date, SRI has helped advance more than 100 drugs into clinical trials,
including a number of its own discoveries, several of which have reached
the market. SRI is also working at the nexus of science and technology to
create new technology platforms for the next generation of drug discovery
and development in areas such as diagnostics, drug delivery, medical
devices, and systems biology.
About SRI International
Silicon Valley-based SRI International (www.sri.com) is one of the world's
leading independent research and technology development organizations. SRI,
which was founded by Stanford University as Stanford Research Institute in
1946 and became independent in 1970, has been meeting the strategic needs
of clients and partners for more than 60 years. Perhaps best known for its
invention of the computer mouse and interactive computing, SRI has also
been responsible for major advances in networking and communications,
robotics, drug discovery and development, advanced materials, atmospheric
research, education research, economic development, national security, and
more. The nonprofit institute performs sponsored research and development
for government agencies, businesses, and foundations. SRI also licenses its
technologies, forms strategic alliances, and creates spin-off companies. In
2008, SRI's consolidated revenues, including its wholly owned for-profit
subsidiary, Sarnoff Corporation, were approximately $490 million.
